NCT03289533 A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) Status COMPLETED Phase PHASE1
NCT03288324 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Status COMPLETED Phase PHASE1/PHASE2
NCT03284723 PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors Status TERMINATED Phase PHASE1
NCT03281304 A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission Status TERMINATED Phase PHASE4
NCT03280173 A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood Status COMPLETED Phase PHASE1
NCT03275740 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Status TERMINATED Phase PHASE1
NCT03275311 Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 Status RECRUITING Phase N/A
NCT03274076 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Status COMPLETED Phase PHASE1/PHASE2
NCT03273842 A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT03271047 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation Status COMPLETED Phase PHASE2
NCT03269695 Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission. Status TERMINATED Phase PHASE2
NCT03269136 PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT03267836 Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma Status TERMINATED Phase PHASE1
NCT03266705 A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood Status COMPLETED Phase PHASE1
NCT03266588 Open Label Safety Study in Acute Treatment of Migraine Status COMPLETED Phase PHASE2/PHASE3
NCT03262662 EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking Status COMPLETED Phase PHASE3